AM
Therapeutic Areas
Oculis Holding AG Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCS-01 | Diabetic Macular Edema (DME) | Phase 3 |
| Licaminlimab (OCS-02) | Dry Eye Disease (DED) | Phase 2/3 |
| Privosegtor (ACT-01) | Optic Neuritis | Phase 2 |
| OCS-02 | Acute Anterior Uveitis | Phase 2 |
Leadership Team at Oculis Holding AG
RS
Riad Sherif, M.D.
Chief Executive Officer
SC
Sylvia Cheung, CPA
Chief Financial Officer
PF
Patricia F. Walker, M.D., Ph.D.
Chief Scientific Officer & Head of Translational Science
CA
Christina Ackermann, J.D.
General Counsel & Chief Compliance Officer
DH
David H. Moore, J.D.
Chief Business Officer
MK
Martijn Kleijwegt
Chairman of the Board
PE
Prof. Einar Stefánsson
Board Member, Co-Founder & Co-Inventor of OPTIREACH®